Key result
Novel human iPSC line successfully models pediatric hypertrophic cardiomyopathy with a TPM1 mutation.
Why the study?
TPM1 mutations cause hypertrophic cardiomyopathy, a major cause of sudden cardiac death in the young, but disease models for studying pathogenesis and drug screening are needed.
The successful generation of an iPSC line with a TPM1 mutation provides a valuable in vitro model for investigating the molecular pathogenesis of hypertrophic cardiomyopathy and future drug screening.
Tropomyosin 1 (TPM1) encodes tropomyosin alpha-1 chain, a key cardiac sarcomere component, while TPM1 mutations cause hypertrophic cardiomyopathy (HCM), a major cause of sudden cardiac death in the young. We generated the human iPSC line ZZUNEUi040-A from peripheral blood mononuclear cells of a 10-year-old male with non-obstructive asymmetric HCM carrying a heterozygous TPM1 c.644C > T (p.Ser215Leu) mutation via Sendai virus non-integrating reprogramming technology. The line showed normal karyotype (46,XY), undifferentiated hPSC-State markers, and trilineage differentiation potential, serving as a valuable model for HCM pathogenesis studies and drug screening.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Hypertrophic cardiomyopathy carrying a heterozygous TPM1 c.644C > T mutation (n=1). Sendai virus non-integrating reprogramming was evaluated on Generation and characterization of human iPSC line ZZUNEUi040-A. The human iPSC line ZZUNEUi040-A was successfully generated from a 10-year-old male with hypertrophic cardiomyopathy carrying a TPM1 c.644C > T mutation, demonstrating normal karyotype and pluripotency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: